Amendment to the Regulations Governing the Determination of Patent Term Extention Come into Effect on July 1, 2023 - 2023年07月14日
TIPO previously required applicants seeking to extend patent terms on pharmaceutical products or manufacturing methods to submit documentation for the duration of all domestic and/or international clinical trials. Documentation was then sent to the Food and Drug Administration (FDA) of the Ministry of Health and Welfare (MOHW), the central competent authority, to confirm the clinical trial period required for issuing a drug license.
For more information, Please visit:
Amendment to the Regulations Governing the Determination of Patent Term Extention Come into Effect on July 1, 2023
Main Menu
知財情報
- TIPO Releases the Patent Trends on Wastewater Treatment and Recycling Technologies in Semiconductor Industry Report - 2024年10月18日
- TIPO Publishes English Version of Patent Examination Guidelines, Part II: Substantive Examination for Invention Patents, Chapter 6 “Amendments” - 2024年10月18日
- TIPO Releases Analysis of Taiwan's Green Trademark Industry – Now Available for the Public! - 2024年09月25日
- Accelerated Examination Program for Reexamination (AEPRe) hits the road on September 1, 2024 - 2024年09月11日
- TIPO’s Revisions of the Patent Examination Guidelines Took Effect on July 1, 2024: Part II Chapter 1, 3, 11, 14 and Part V Chapter 1 - 2024年08月30日
台湾特許主な業務
台湾特許出願
特許等明細書の翻訳文献翻訳
出願前・審査請求時に行う調査
意見書・手続補正書の作成
料金納付 - 設定登録
料金納付 - 年金納付
その他審判事件（無効・訂正）
Website QR Code
| 遠 碩 專 利 師 事 務 所 | |
| Lewis & Davis Patent Attorneys Office | 12 Fl. No. 290, Fuxing N. Rd. Taipei 10478, Taiwan |
| TEL：+886-2-2517-5955 FAX：+886-2-2517-8517 | E-mail：このメールアドレスはスパムボットから保護されています。閲覧するにはJavaScriptを有効にする必要があります。 |